PHOTOFRIN (porfimer sodium) injection – full prescribing information (2026)

Government Record · Pinnacle Biologics, Inc.; FDA-approved labeling via DailyMed (US NLM) · April 28, 2026

Pinnacle Biologics et al., 2026-04-28: US label for porfimer sodium (Photofrin), the classic PDT drug: its approved indications are oesophageal cancer, endobronchial non-small-cell lung cancer and Barrett's high-grade dysplasia – not skin, bladder or brain cancer in the United States.

Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy

Section 1 (Indications and Usage)

Pinnacle Biologics et al., 2026-04-28: US label for porfimer sodium (Photofrin), the classic PDT drug: its approved indications are oesophageal cancer, endobronchial non-small-cell lung cancer and Barrett's high-grade dysplasia – not skin, bladder or brain cancer in the United States. C8 label record – approved photosensitizer list. Country: USA. Not methylene blue. Porfimer sodium is nonetheless the agent used in the published clinical bladder and glioma PDT series (see the Nseyo 1998 and Muller 1996 rows) – i.e. the clinical PDT record belongs to porphyrins, in and beyond their labelled indications. Study type: regulatory record.